Share Email Print

Journal of Biomedical Optics • Open Access

Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy

Paper Abstract

The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for the study. A strong correlation ([i]r=0.57 ) was found for bulk intensity measurements of T1-weighted gadolinium enhancement and verteporfin fluorescence in the tumor region of interest. The use of contrast-enhanced MR imaging shows promise as a method for treatment planning and photosensitizer dosimetry in human photodynamic therapy (PDT) of pancreas cancer.

Paper Details

Date Published: 23 December 2013
PDF: 4 pages
J. Biomed. Opt. 18(12) 120504 doi: 10.1117/1.JBO.18.12.120504
Published in: Journal of Biomedical Optics Volume 18, Issue 12
Show Author Affiliations
Kimberley S. Samkoe, Geisel School of Medicine (United States)
Amber Bryant, Thayer School of Engineering at Dartmouth (United States)
Jason R. Gunn, Thayer School of Engineering at Dartmouth (United States)
Stephen P. Pereira, Univ. College London (United Kingdom)
Tayyaba Hasan, Massachusetts General Hospital (United States)
Brian W. Pogue, Thayer School of Engineering at Dartmouth (United States)

© SPIE. Terms of Use
Back to Top